Zydus Lifesciences Ltd introduces Sitaglyn & Siglyn (Sitagliptin) for the treatment of Type 2 diabetes in India

Zydus Lifesciences Ltd. today launched Sitagliptin under the brand names Sitaglyn and Siglyn in India to treat Type 2 diabetes.

Sitaglyn and Siglyn will contribute to a comprehensive solution for Type 2 diabetes management by providing patients with access to quality care at a cost that is approximately 60% less than the originator.

Sitagliptin is the gold standard in the Dipeptidyl peptidase 4 inhibitor (DPP4i) category, accounting for more than 62% of the global market.

With a proven safety profile, the drug achieves best-in-class Hemoglobin A1C (HbA1c) goals.

The oral anti-diabetic market in India is worth Rs 125 billion, with the DPP4i class accounting for more than Rs 40 billion.